Current Report Filing (8-k)
June 12 2018 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 12, 2018
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
|
|
|
|
|
England and Wales
|
|
0-21392
|
|
Not applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
2 Pembroke House, Upper Pembroke Street
28-32,
Dublin
2,
Ireland
|
|
Not applicable
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: +353 1 6699 020
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01. Other Events.
On June 12, 2018, Amarin announced that it had entered into a collaboration agreement with Mochida Pharmaceutical Co., Ltd.
(Mochida), an integrated Japanese pharmaceutical company. The collaboration agreement is focused on the development and commercialization of early-stage drug products based on
omega-3
acid EPA
(eicosapentaenoic acid). Under the collaboration agreement Amarin will, among other things, obtain an exclusive license to certain Mochida technology to develop, manufacture and commercialize new drug products that contain high purity EPA for the
United States and other territories. Under the collaboration agreement, Amarin will pay Mochida anon-refundable,
non-creditable
upfront payment of $2.7 million, and may be obligated to pay milestone
payments and royalties on net sales of future products arising from the collaboration, if any.
Amarins management expects that
expenditures related to research and development activities for product candidates under the collaboration agreement will be immaterial in 2018 and less than $5.0 million in 2019.
A press release regarding the foregoing is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Forward-looking statements
This Current Report on Form
8-K
contains forward-looking statements, including expectations regarding future clinical
development activities, drug development collaboration activities, and amounts to be incurred or payable in connection with the Mochida collaboration. These forward-looking statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated with drug development and dependence of third parties. A further list and description of
these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarins filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form
10-Q.
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 12, 2018
|
|
|
|
Amarin Corporation plc
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John Thero
|
|
|
|
|
|
|
John Thero
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024